Lyra Therapeutics, Inc. (LYRA)

NASDAQ: LYRA · Real-Time Price · USD

1.455

+0.005 (0.34%)

Feb 24, 2026, 4:00 PM EST - Market closed

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Developing Targeted Medicines to Address ENT Diseases	1.53M	1.56M	1.36M	285.00K			1.24M
Developing Targeted Medicines to Address ENT Diseases Growth	-1.54%	14.31%	378.25%	-			-
Total	1.53M	1.56M	1.36M	285.00K			1.24M
Total Growth	-1.54%	14.31%	378.25%	-			-

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
United States	1.53M	1.56M	1.36M	285.00K			1.24M
United States Growth	-1.54%	14.31%	378.25%	-			-
Total	1.53M	1.56M	1.36M	285.00K			1.24M
Total Growth	-1.54%	14.31%	378.25%	-			-

Source: S&P Global Market Intelligence.